NCT04632108View on ClinicalTrials.gov

A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

199

Participants

Timeline

Start Date

January 28, 2021

Primary Completion Date

October 31, 2025

Study Completion Date

December 31, 2025

Conditions
Malignant Solid Tumor
Interventions
DRUG

ASKB589 Injection

ASKB589 Injection with dose escalation stage of 0.3mg/kg up to 20mg/kg,as well as dose expansion stage with recommended dose level from dose escalation stage.

Trial Locations (2)

100089

Beijing cancer hospital, Beijing

276000

Linyi cancer hospital, Linyi

Sponsors
All Listed Sponsors
collaborator

Jiangsu Aosaikang Biopharmaceutical Co., Ltd

UNKNOWN

lead

Jiangsu Aosaikang Pharmaceutical Co., Ltd.

INDUSTRY